argenx SE (NASDAQ:ARGX) Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its position in argenx SE (NASDAQ:ARGX) by 38,152.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 144,211 shares of the company’s stock after purchasing an additional 143,834 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.24% of argenx worth $89,391,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Marks Group Wealth Management Inc raised its holdings in shares of argenx by 11.7% in the 4th quarter. Marks Group Wealth Management Inc now owns 1,316 shares of the company’s stock valued at $809,000 after buying an additional 138 shares during the period. Stephens Inc. AR acquired a new stake in shares of argenx during the fourth quarter worth about $310,000. Wilmington Savings Fund Society FSB boosted its stake in shares of argenx by 47.8% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 1,776 shares of the company’s stock valued at $1,092,000 after purchasing an additional 574 shares during the period. Advisors Preferred LLC acquired a new position in shares of argenx in the fourth quarter valued at approximately $73,000. Finally, Financial Advocates Investment Management purchased a new stake in argenx during the 4th quarter worth approximately $237,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Performance

argenx stock opened at $649.09 on Thursday. The company has a market capitalization of $39.44 billion, a P/E ratio of -737.60 and a beta of 0.58. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The stock has a 50-day simple moving average of $638.76 and a 200-day simple moving average of $580.34.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ARGX shares. Wedbush reissued an “outperform” rating and issued a $655.00 price target on shares of argenx in a research report on Tuesday, December 3rd. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Piper Sandler upped their price target on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. JMP Securities lifted their price objective on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. Finally, Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and upped their target price for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, argenx presently has a consensus rating of “Moderate Buy” and an average price target of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.